These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 29230672)

  • 1. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.
    Sanchez E; Smith EJ; Yashar MA; Patil S; Li M; Porter AL; Tanenbaum EJ; Schlossberg RE; Soof CM; Hekmati T; Tang G; Wang CS; Chen H; Berenson JR
    Target Oncol; 2018 Feb; 13(1):39-47. PubMed ID: 29230672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker.
    Sanchez E; Tanenbaum EJ; Patil S; Li M; Soof CM; Vidisheva A; Waterman GN; Hekmati T; Tang G; Wang CS; Chen H; Berenson J
    Expert Rev Mol Diagn; 2018 Apr; 18(4):319-329. PubMed ID: 29504446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
    Sanchez E; Gillespie A; Tang G; Ferros M; Harutyunyan NM; Vardanyan S; Gottlieb J; Li M; Wang CS; Chen H; Berenson JR
    Clin Cancer Res; 2016 Jul; 22(13):3383-97. PubMed ID: 26960399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
    Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
    J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
    Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
    J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Evaluation of STI-8811, a Novel Antibody-Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma.
    Springer AD; Wang R; Wang J; Du Q; Pi W; Nguyen AQ; Li X; Khasanov A; Zhu T; Yan Z; Hong Y; Zhou H; Zhang Y; Kerwin L; Li L; Ji H; Zhang H
    Cancer Res Commun; 2024 Oct; 4(10):2660-2672. PubMed ID: 39292169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma.
    Meinl E; Krumbholz M
    Curr Opin Immunol; 2021 Aug; 71():117-123. PubMed ID: 34330018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma.
    Lee H; Durante M; Skerget S; Vishwamitra D; Benaoudia S; Ahn S; Poorebrahim M; Barakat E; Jung D; Leblay N; Ziccheddu B; Diamond B; Papadimitriou M; Cohen AD; Landgren O; Neri P; Maura F; Bahlis NJ
    Blood; 2024 Dec; 144(25):2637-2651. PubMed ID: 39321344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
    Chen H; Li M; Xu N; Ng N; Sanchez E; Soof CM; Patil S; Udd K; Bujarski S; Cao J; Hekmati T; Ghermezi M; Zhou M; Wang EY; Tanenbaum EJ; Zahab B; Schlossberg R; Yashar MA; Wang CS; Tang GY; Spektor TM; Berenson JR
    Leuk Res; 2019 Jun; 81():62-66. PubMed ID: 31035033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
    Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M
    Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma.
    Seipel K; Porret N; Wiedemann G; Jeker B; Bacher VU; Pabst T
    Curr Issues Mol Biol; 2022 Mar; 44(4):1463-1471. PubMed ID: 35723356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma.
    Dalla Palma B; Marchica V; Catarozzo MT; Giuliani N; Accardi F
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32961764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-BCMA antibodies in the future management of multiple myeloma.
    Gavriatopoulou M; Ntanasis-Stathopoulos I; Dimopoulos MA; Terpos E
    Expert Rev Anticancer Ther; 2019 Apr; 19(4):319-326. PubMed ID: 30810049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation.
    Chen H; Yu T; Lin L; Xing L; Cho SF; Wen K; Aardalen K; Oka A; Lam J; Daley M; Lu H; Munshi N; Anderson KC; Tai YT
    Blood Cancer J; 2022 Aug; 12(8):118. PubMed ID: 35973981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 19. Soluble B-cell maturation antigen in multiple myeloma.
    Costa BA; Ortiz RJ; Lesokhin AM; Richter J
    Am J Hematol; 2024 Apr; 99(4):727-738. PubMed ID: 38270277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement.
    Schuh E; Musumeci A; Thaler FS; Laurent S; Ellwart JW; Hohlfeld R; Krug A; Meinl E
    J Immunol; 2017 Apr; 198(8):3081-3088. PubMed ID: 28283566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.